Trial Profile
Assessing The Effectiveness and safety of Nasal NeuroEpo management in patients with Alzheimer's mild/moderate - ATHENEA
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ATHENEA
- 31 Jul 2020 Status changed from not yet recruiting to recruiting as per Results presented at the Alzheimer's Association International Conference 2020
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020
- 04 Nov 2019 Planned initiation date changed from 1 May 2017 to 11 Dec 2017.